New in vitro data showing matinas biopharma's lnc platform delivering small oligonucleotides presented at tides usa 2024

Bedminster, n.j., may 16, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces new in vitro data showing the use of lncs for the delivery of small oligonucleotides was presented yesterday in a poster session at tides usa 2024: oligonucleotide & peptide therapeutics, a hybrid in-person and virtual conference underway in boston.
MTNB Ratings Summary
MTNB Quant Ranking